To ask Her Majesty's Government what assessment they have made of the adequacy of funding for COVAX to enable the (1) purchase, and (2) distribution, of ancillary vaccination equipment; and what assessment have they made of its implications for the delivery of vaccination programmes in the developing world.
The UK is committed to help bring the acute phase of the pandemic to an end and strongly supports the COVAX Facility as a key multilateral mechanism to deliver this. The UK is one of the largest donors to COVAX's Advance Market Commitment (AMC), committing £548 million, and will donate 100 million vaccine doses by mid-2022. This support has helped COVAX deliver over 1 billion vaccines worldwide so far.
The UK has worked closely with COVAX on its recently published investment opportunity, including its financing assessments for the purchase and distribution of ancillary vaccination equipment. There are many barriers to effective rollout and the UK and COVAX partners are working with countries to help health systems deliver vaccines. This includes engaging with communities and leaders to build trust, provide correct information, and encourage uptake.